Skip to main content

Table 4 Type of and reason for index therapy change within 6 months and full study period among patients who changed, N (%)

From: A multicenter, retrospective chart review study comparing index therapy change rates in open-angle glaucoma or ocular hypertension patients newly treated with latanoprost or travoprost-Z monotherapy

 

Within 6 months

Across full study period

 

Latanoprost

N = 134

Travoprost-Z

N = 77

Latanoprost

N = 218

Travoprost-Z

N = 121

Type of change

    

   Add-on

36 (26.9)

26 (33.8)

62 (28.4)

40 (33.1)

   Switch

65 (48.5)

36 (46.8)

102 (46.8)

50 (41.3)

   Discontinuation

14 (10.5)

5 (6.5)

23 (10.6)

13 (10.7)

   Surgery/procedure

19 (14.2)

10 (13.0)

31 (14.2)

18 (14.9)

Reason for change*

    

   IOP not controlled

83 (61.9)

50 (64.9)

119 (54.6)

76 (62.8)

   Adverse events

16 (11.9)

16 (20.8)

24 (11.0)

18 (14.9)

   Physician preference

11 (8.2)

4 (5.2)

21 (9.6)

9 (7.4)

   Non-compliance

8 (6.0)

2 (2.6)

11 (5.0)

6 (5.0)

   Cost

9 (6.7)

3 (3.9)

19 (8.7)

4 (3.3)

   Patient request

5 (3.7)

2 (2.6)

10 (4.6)

4 (3.3)

   Ocular nerve head

    

changes

1 (0.7)

0

6 (2.8)

1 (0.8)

   Other

11 (8.2)

3 (3.9)

25 (11.5)

5 (4.1)

  1. IOP = intraocular pressure.
  2. *Reported by ≥2% of patients in either cohort at either time point. More than one reason could be reported for each patient.